Does the media favor INSM or REGN?

In the previous week, Regeneron Pharmaceuticals had 37 more articles in the media than Insmed. MarketBeat recorded 48 mentions for Regeneron Pharmaceuticals and 11 mentions for Insmed. Insmed's average media sentiment score of 1.15 beat Regeneron Pharmaceuticals' score of 0.70 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 19 Very Positive mention(s) 4 Positive mention(s) 21 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ARGX or INSM?

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 14.50 $1.29B $26.04 37.80 Insmed $606.42M 46.60 -$1.28B -$4.11 N/A

Is ARGX or INSM more profitable?

argenex has a net margin of 32.19% compared to Insmed's net margin of -76.94%. argenex's return on equity of 43.59% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Insmed -76.94% -123.94% -44.30%

Does the media prefer ARGX or INSM?

In the previous week, Insmed had 5 more articles in the media than argenex. MarketBeat recorded 11 mentions for Insmed and 6 mentions for argenex. Insmed's average media sentiment score of 1.15 beat argenex's score of 0.72 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, INSM or MRNA?

Insmed has higher earnings, but lower revenue than Moderna. Insmed is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 46.60 -$1.28B -$4.11 N/A Moderna $2.21B 26.01 -$2.82B -$7.99 N/A

Is INSM or MRNA more profitable?

Insmed has a net margin of -76.94% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Moderna -141.43% -28.30% -19.39%

Does the media favor INSM or MRNA?

In the previous week, Moderna had 16 more articles in the media than Insmed. MarketBeat recorded 27 mentions for Moderna and 11 mentions for Insmed. Insmed's average media sentiment score of 1.15 beat Moderna's score of 0.55 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 9 Very Positive mention(s) 8 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings & valuation, INSM or NTRA?

Natera has higher revenue and earnings than Insmed. Natera is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 46.60 -$1.28B -$4.11 N/A Natera $2.31B 20.56 -$208.16M -$1.36 N/A

Is INSM or NTRA more profitable?

Natera has a net margin of -7.11% compared to Insmed's net margin of -76.94%. Natera's return on equity of -11.38% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Natera -7.11% -11.38% -7.87%

Does the media favor INSM or NTRA?

In the previous week, Natera had 8 more articles in the media than Insmed. MarketBeat recorded 19 mentions for Natera and 11 mentions for Insmed. Natera's average media sentiment score of 1.21 beat Insmed's score of 1.15 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RVMD or INSM?

In the previous week, Revolution Medicines had 3 more articles in the media than Insmed. MarketBeat recorded 14 mentions for Revolution Medicines and 11 mentions for Insmed. Revolution Medicines' average media sentiment score of 1.20 beat Insmed's score of 1.15 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Insmed (INSM) Competitors

$129.41 +2.13 (+1.67%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$129.22 -0.19 (-0.14%)

As of 09/11/2026 07:56 PM Eastern

Compare

INSM vs. REGN, ARGX, MRNA, NTRA, and RVMD

Should you buy Insmed stock or one of its competitors? Insmed's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Insmed compare to Regeneron Pharmaceuticals?

Insmed (NASDAQ:INSM) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Insmed has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	46.60	-$1.28B	-$4.11	N/A
Regeneron Pharmaceuticals	$15.53B	5.18	$4.50B	$40.46	19.32

Insmed currently has a consensus price target of $205.52, suggesting a potential upside of 58.81%. Regeneron Pharmaceuticals has a consensus price target of $802.18, suggesting a potential upside of 2.65%. Given Insmed's stronger consensus rating and higher probable upside, research analysts plainly believe Insmed is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Insmed's net margin of -76.94%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

In the previous week, Regeneron Pharmaceuticals had 37 more articles in the media than Insmed. MarketBeat recorded 48 mentions for Regeneron Pharmaceuticals and 11 mentions for Insmed. Insmed's average media sentiment score of 1.15 beat Regeneron Pharmaceuticals' score of 0.70 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	19 Very Positive mention(s)	4 Positive mention(s)	21 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Regeneron Pharmaceuticals beats Insmed on 10 of the 17 factors compared between the two stocks.

How does Insmed compare to argenex?

argenex (NASDAQ:ARGX) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	14.50	$1.29B	$26.04	37.80
Insmed	$606.42M	46.60	-$1.28B	-$4.11	N/A

argenex has a net margin of 32.19% compared to Insmed's net margin of -76.94%. argenex's return on equity of 43.59% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Insmed	-76.94%	-123.94%	-44.30%

In the previous week, Insmed had 5 more articles in the media than argenex. MarketBeat recorded 11 mentions for Insmed and 6 mentions for argenex. Insmed's average media sentiment score of 1.15 beat argenex's score of 0.72 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex presently has a consensus price target of $1,158.61, suggesting a potential upside of 17.70%. Insmed has a consensus price target of $205.52, suggesting a potential upside of 58.81%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

60.3% of argenex shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Insmed has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

Summary

argenex beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Insmed compare to Moderna?

Insmed (NASDAQ:INSM) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Insmed has higher earnings, but lower revenue than Moderna. Insmed is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	46.60	-$1.28B	-$4.11	N/A
Moderna	$2.21B	26.01	-$2.82B	-$7.99	N/A

75.3% of Moderna shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Insmed has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Moderna has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

In the previous week, Moderna had 16 more articles in the media than Insmed. MarketBeat recorded 27 mentions for Moderna and 11 mentions for Insmed. Insmed's average media sentiment score of 1.15 beat Moderna's score of 0.55 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	9 Very Positive mention(s)	8 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Insmed presently has a consensus target price of $205.52, indicating a potential upside of 58.81%. Moderna has a consensus target price of $76.72, indicating a potential downside of 46.71%. Given Insmed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Insmed is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

Insmed has a net margin of -76.94% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Moderna	-141.43%	-28.30%	-19.39%

Summary

Insmed beats Moderna on 9 of the 17 factors compared between the two stocks.

How does Insmed compare to Natera?

Insmed (NASDAQ:INSM) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Natera has a net margin of -7.11% compared to Insmed's net margin of -76.94%. Natera's return on equity of -11.38% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Natera	-7.11%	-11.38%	-7.87%

99.9% of Natera shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 5.1% of Natera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Insmed has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

Insmed presently has a consensus target price of $205.52, suggesting a potential upside of 58.81%. Natera has a consensus target price of $330.83, suggesting a potential upside of 0.58%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Insmed is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Natera has higher revenue and earnings than Insmed. Natera is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	46.60	-$1.28B	-$4.11	N/A
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A

In the previous week, Natera had 8 more articles in the media than Insmed. MarketBeat recorded 19 mentions for Natera and 11 mentions for Insmed. Natera's average media sentiment score of 1.21 beat Insmed's score of 1.15 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Natera beats Insmed on 11 of the 16 factors compared between the two stocks.

How does Insmed compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

94.3% of Revolution Medicines shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

In the previous week, Revolution Medicines had 3 more articles in the media than Insmed. MarketBeat recorded 14 mentions for Revolution Medicines and 11 mentions for Insmed. Revolution Medicines' average media sentiment score of 1.20 beat Insmed's score of 1.15 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines currently has a consensus price target of $226.17, suggesting a potential upside of 10.99%. Insmed has a consensus price target of $205.52, suggesting a potential upside of 58.81%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Revolution Medicines has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A
Insmed	$606.42M	46.60	-$1.28B	-$4.11	N/A

Revolution Medicines has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Revolution Medicines' return on equity of -88.20% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Insmed	-76.94%	-123.94%	-44.30%

Summary

Revolution Medicines beats Insmed on 9 of the 15 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INSM vs. The Competition

Export

Metric	Insmed	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$27.80B	$3.86B	$7.15B	$12.71B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-31.49	14.11	272.98	25.27
Price / Sales	46.60	1,449.22	646.20	90.55
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	37.40	15.13	10.33	6.20
Net Income	-$1.28B	-$22.82M	$3.49B	$358.27M
7 Day Performance	2.47%	-4.31%	-3.33%	-2.36%
1 Month Performance	-2.17%	0.00%	-0.42%	-2.77%
1 Year Performance	-11.32%	40.67%	19.22%	7.64%

Insmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INSM Insmed	3.42 of 5 stars	$129.41 +1.7%	$205.52 +58.8%	-11.2%	$27.80B	$606.42M	N/A	1,664	News Coverage Positive News Insider Trade
REGN Regeneron Pharmaceuticals	3.8196 of 5 stars	$827.72 flat	$800.36 -3.3%	+37.5%	$85.22B	$14.34B	20.46	15,410	Trending News Analyst Forecast
ARGX argenex	4.5486 of 5 stars	$1,033.15 flat	$1,158.61 +12.1%	+28.9%	$64.63B	$4.25B	39.68	1,863
MRNA Moderna	2.1333 of 5 stars	$145.55 flat	$76.72 -47.3%	+467.0%	$58.11B	$1.94B	N/A	4,700	Trending News Analyst Forecast
NTRA Natera	2.1538 of 5 stars	$328.18 flat	$319.38 -2.7%	+89.2%	$47.31B	$2.31B	N/A	6,140	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INSM) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insmed (INSM) Competitors

INSM vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Insmed compare to Regeneron Pharmaceuticals?

Summary

How does Insmed compare to argenex?

Summary

How does Insmed compare to Moderna?

Summary

How does Insmed compare to Natera?

Summary

How does Insmed compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insmed (INSM) Competitors

INSM vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Insmed compare to Regeneron Pharmaceuticals?

Which has more risk and volatility, INSM or REGN?

Which has preferable earnings and valuation, INSM or REGN?

Do analysts prefer INSM or REGN?

Do institutionals and insiders hold more shares of INSM or REGN?

Is INSM or REGN more profitable?

Does the media favor INSM or REGN?

Summary

How does Insmed compare to argenex?

Which has higher valuation and earnings, ARGX or INSM?

Is ARGX or INSM more profitable?

Does the media prefer ARGX or INSM?

Do analysts prefer ARGX or INSM?

Do institutionals & insiders have more ownership in ARGX or INSM?

Which has more risk & volatility, ARGX or INSM?

Summary

How does Insmed compare to Moderna?

Which has preferable valuation and earnings, INSM or MRNA?

Do insiders & institutionals believe in INSM or MRNA?

Which has more volatility and risk, INSM or MRNA?

Does the media favor INSM or MRNA?

Do analysts recommend INSM or MRNA?

Is INSM or MRNA more profitable?

Summary

How does Insmed compare to Natera?

Is INSM or NTRA more profitable?

Do insiders and institutionals have more ownership in INSM or NTRA?

Which has more volatility and risk, INSM or NTRA?

Do analysts rate INSM or NTRA?

Which has stronger earnings & valuation, INSM or NTRA?

Does the media favor INSM or NTRA?

Summary

How does Insmed compare to Revolution Medicines?

Do insiders and institutionals hold more shares of RVMD or INSM?

Which has more risk and volatility, RVMD or INSM?

Does the media refer more to RVMD or INSM?

Do analysts recommend RVMD or INSM?

Which has higher earnings and valuation, RVMD or INSM?

Is RVMD or INSM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools